Craig-Hallum Initiates Coverage On Satellos Bioscience with Buy Rating, Announces Price Target of $24
Craig-Hallum analyst Adam Vogel initiates coverage on Satellos Bioscience (NASDAQ:MSLE) with a Buy rating and announces Price Target of $24.
Stocks · News reference
Satellos Bioscience Announces WHO Assigned International Nonproprietary Name Forazapadin To SAT-3247; Says BASECAMP Enrollment Expected To Complete This Quarter, Clinical Data In Q4
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Satellos Granted US Patent Covering Lead Drug Candidate Forazapadin And Broader AAK1 Inhibitor Platform
Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL), a clinical-stage drug development company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced that the United States
Satellos Bioscience Completes Enrollment For BASECAMP, Phase 2 Clinical Trial Evaluating Forazapadin For Treatment Of Duchenne Muscular Dystrophy In Ambulatory Boys 7 To 10 Years Of Age
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development
Satellos Bioscience received FDA clearance for its IND application to test forazapadin in facioscapulohumeral muscular dystrophy (FSHD), expanding the drug candidate into a second degenerative muscle disease. The FSHD Canada Foundation will provide up to US$5 million in non-dilutive financing to support clinical development, with a Phase 2 study expected to begin in Q4 2026. Forazapadin is an AAK1 inhibitor designed to restore muscle repair and regeneration.